title: Cancer prevention in the era of precision oncology.
abstract: Cancer is a highly heterogeneous disease, both between and within different target organs. Precision cancer prevention requires understanding the molecular pathways leading to cancer on a "per-person" level, identification of individuals most at risk for developing cancer, and tailoring interventions to accommodate pathogenesis, risk, and individual responses to interventions. This commentary will discuss how an investment in precision prevention research can accelerate cancer prevention agent development-the key to reducing cancer incidence and mortality.
authors.affiliation: Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.|Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
authors.forename: N N
authors.initials: NN
authors.lastname: Brahme
authors.affiliation: Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
authors.forename: E
authors.initials: E
authors.lastname: Szabo
mesh_terms: D006801:Humans; D008495:Medical Oncology / Q000592:standards / Q000639:trends*; D009369:Neoplasms / Q000517:prevention & control*; D057285:Precision Medicine / Q000592:standards / Q000639:trends*